582 related articles for article (PubMed ID: 18549871)
1. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
Corson MA; Jones PH; Davidson MH
Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
Anderson JL
Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
[TBL] [Abstract][Full Text] [Related]
3. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
Davidson MH; Corson MA; Alberts MJ; Anderson JL; Gorelick PB; Jones PH; Lerman A; McConnell JP; Weintraub HS
Am J Cardiol; 2008 Jun; 101(12A):51F-57F. PubMed ID: 18549872
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk?
Lee JH; Engler MM
Prog Cardiovasc Nurs; 2009 Dec; 24(4):181-9. PubMed ID: 20002343
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein-associated phospholipase A2 and risk of stroke.
Gorelick PB
Am J Cardiol; 2008 Jun; 101(12A):34F-40F. PubMed ID: 18549870
[TBL] [Abstract][Full Text] [Related]
6. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
7. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor?
Lerman A; McConnell JP
Am J Cardiol; 2008 Jun; 101(12A):11F-22F. PubMed ID: 18549867
[TBL] [Abstract][Full Text] [Related]
9. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.
Toth PP; McCullough PA; Wegner MS; Colley KJ
Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):425-38. PubMed ID: 20222820
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
12. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
13. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes.
Noto H; Chitkara P; Raskin P
J Diabetes Complications; 2006; 20(6):343-8. PubMed ID: 17070436
[TBL] [Abstract][Full Text] [Related]
14. Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease.
Epps KC; Wilensky RL
J Intern Med; 2011 Jan; 269(1):94-106. PubMed ID: 21054587
[TBL] [Abstract][Full Text] [Related]
15. Identifying the vulnerable patient with rupture-prone plaque.
Weintraub HS
Am J Cardiol; 2008 Jun; 101(12A):3F-10F. PubMed ID: 18549869
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
Khakpour H; Frishman WH
Cardiol Rev; 2009; 17(5):222-9. PubMed ID: 19690473
[TBL] [Abstract][Full Text] [Related]
17. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
18. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study.
Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM
J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676
[TBL] [Abstract][Full Text] [Related]
19. Non-conventional markers of atherosclerosis before and after gastric banding surgery.
Hanusch-Enserer U; Zorn G; Wojta J; Kopp CW; Prager R; Koenig W; Schillinger M; Roden M; Huber K
Eur Heart J; 2009 Jun; 30(12):1516-24. PubMed ID: 19380349
[TBL] [Abstract][Full Text] [Related]
20. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
Persson M; Hedblad B; Nelson JJ; Berglund G
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1411-6. PubMed ID: 17431184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
